Search   |   Print Page   |   Contact Us   |   Sign In   |   Join
Community Search
MDG Advisory Board
Share |


MDG Mission

The MDG mission is to serve its members with ongoing education, peer-to-peer discussion and networking.

With the rapidly expanding biotech community in Boston, the corresponding expanding scope of our mission demands new initiatives in order to remain current and relevant to the members.


NEW MDG Boston Advisory Board

Accordingly, MDG has formed an Advisory Board consisting of seven outstanding individuals, chaired by the MDG President. These board members, derived from industry, healthcare and academia, will report to and advise the President.


Their purpose is to suggest new educational programs, new directions and new resources in the biomedical community. Their credentials are impeccable, their participation is a testimony to our goals and an honor to our organization. Ultimately, the Advisory Board serves the members of MDG and the attendees of the forums and the other events we organize.


The Medical Development Group of Boston is the largest and oldest non-profit, volunteer organization whose members are individual professionals interested in medical technology and development, and in the benefits accruing to society, industry, healthcare and academia. In 2015 interest in MDG grew with attendance at its monthly forums increasing by about 66%.


A PDF of the Advisory Board can be downloaded here 




Peter N. Madras M.D. as President of MDG Boston is Chair of the Advisory Board. Dr. Madras graduated McGill Medical School and trained in surgery at Boston City Hospital and Harvard Medical School, along with a fellowship at the University of Toronto, after which he was Associate Professor of Surgery at Harvard Medical School, practicing at the New England Deaconess Hospital.


He was Director of the Medical Group of the Avco Everett Research Laboratory which developed cardiac assist devices which are still in use today. He also was Medical Director of Grace Biomedical in the development of Liver Support Systems and an artificial pancreas, as well as other consulting positions.


Dr. Madras was appointed by the State Governor to serve on and chair the Massachusetts Board of Registration in Medicine and was commissioned by Harvard Medical International to assemble a team to develop the regulations for the Practice of Medicine in the Dubai Healthcare City.


Now retired from the active practice of surgery, Dr. Madras is Senior Staff at the Lahey Hospital, is core faculty at the MIT Sloane School and has been president of MDG for just over one year.



Rafik Attia, M.D. is an esteemed anesthesiologist with 40 years of practice experience. He trained in Egypt and the UK, worked and taught at the Massachusetts General on first coming to Boston and then helped establish the largest anesthesia practice in the Northeast.


Dr. Attia consulted to Siemans and Analogic about operating room equipment and design. Dr. Attia has maintained a career long interest in health care policy. He is the only person selected by two governors for two complete terms serving on the Massachusetts Board of Registration in Medicine which he chaired. At the behest of Harvard Medical International, Rafik helped lead a team of attorneys and physicians to write the regulations for the Practice of Medicine in the Dubai Healthcare City.



John L. Brooks III, MS, BBA is the President and Chief Executive Officer of Arete Worldwide LLC. Arete accelerates and scales innovative solutions in obesity, pre-diabetes, and diabetes through an open, collaborative, and global network of committed thought leaders, partners, research and clinical innovators, donors, and entrepreneurs. Mr. Brooks is the former President and Chief Executive Officer of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization.


Mr. Brooks is a well-known life sciences executive. He has co-founded six life sciences companies, including Insulet (PODD), a disruptive insulin delivery company. He is a principal of Healthcare Capital LLC, which advises early-stage life sciences companies, and he was a co-founder of Prism Venture Partners, a $1.25B venture capital firm.


Previously, Mr. Brooks was the Emerging Business Group General Manager at Pfizer/Valleylab, where he was responsible for Pfizer’s Hospital Products Group’s minimally invasive surgery and new medical technologies businesses. As President/General Manager at Pfizer/Strato, he led the growth of a rapidly evolving vascular access medical device business.



Richard J. Cohen M.D., Ph.D. is the Whitaker Professor in Biomedical Engineering in the Institute for Medical Engineering and Science (IMES) at the Massachusetts Institute of Technology (MIT) and in the Harvard-MIT Health Sciences and Technology (HST) program.


He received an MD degree from Harvard Medical School and PhD degree in physics from MIT. He

trained in internal medicine and cardiology at the Peter Bent Brigham Hospital (now the Brigham and Women’s Hospital).


Dr. Cohen’s research has been in the application of physics, engineering and mathematics to solving problems in medicine – in particular with regard to the cardiovascular system. He has authored over 250 journal articles and is an inventor on more than 30 US patents. He directed HST’s Quantitative Cardiovascular Physiology, Modeling and Data Analysis.


For ten years he led the Cardiovascular Alterations team, composed of investigators from across the country, at the NASA sponsored National Space Biomedical Research Institute. Dr. Cohen has taught courses in a wide range subjects including quantitative physiology, cardiovascular pathophysiology, pharmacology, cell and tissue biophysics, and biomedical enterprise.


Dr. Cohen has consulted for many biomedical companies, served on boards of directors and scientific advisory boards, and made presentations on a number of occasions at the US Centers for Medicare & Medicaid Services. Dr. Cohen has also has served as an expert witness in patent litigation cases. For nine years he co-directed a combined MS/MBA program run jointly by HST and the MIT Sloan School of Management.




Teo Forcht Dagi, M.D. DMedSc, MBA, FRCSEd, DHC Director of Life Sciences, Anglo Scientific

A neurosurgeon, neuroscientist and venture capitalist, Dr. Dagi is recognized as a pioneer in the use of artificial intelligence engines for decision support in neurosurgery, in neuromodulation and in the management of head trauma.


Trained at the MGH and in London, his research interests include the electrophysiology of the limbic system, temporal lobe epilepsy, head trauma and brain tumors. More recently, he has concentrated on biomedical innovation, healthcare IT, clinical decision support and patient safety. He has consulted for the FDA and other government agencies, and is a frequent speaker internationally on translational medicine and translational surgery.


Teo has served as a director to many privately held and publicly listed companies. He is an Overseer of the Beth Israel Deaconess Medical Center, chairs the Council for Surgical and Perioperative Safety, and serves as an editor of Neurosurgery and as an advisor to Broadview Ventures. He holds faculty appointments at Harvard Medical School and Queen’s University Belfast.



Bernard Gordon, Ph.D. is one of the world’s preeminent engineers and inventors. He holds more than 100 U.S. patents, many more worldwide, for breakthrough technologies including those related to instant imaging CT scanning, the fetal heart monitor, and digital Doppler radar.


Dr. Gordon has often been called the “father” of modern analog-to-digital conversion for his many contributions to the communication and medical instrumentation technologies that help enrich our lives. He was awarded the National Medal of Technology by President Reagan in 1986 and elected to the National Academy of Engineering in 1991.


Dr. Gordon has also spent decades supporting innovation in education. He established the National Academy of Engineering’s Bernard M. Gordon Prize for Engineering Leadership Education and has created Engineering Leadership programs at Tufts University, M.I.T., Northeastern University, The Technion, The Citadel, and the University of California, San Diego, among others.


He has provided active leadership on a number of boards in the fields of engineering, healthcare, and higher education – including as Chairman of the Board of Photo Diagnostic Systems, Inc. and as founder and former Chairman of Analogic Corporation. Board colleagues consistently praise his integrity, values and remarkable generosity, as well as his direct impact on the success of numerous start-up companies and educational and medical institutions in the region.


John A Libertino, M.D. After graduating from the Georgetown University school of Medicine, Dr. Libertino trained in General Surgery at Strong Memorial Hospital of the University of Rochester School of Medicine and completed his Urology Residency at the Yale University School of Medicine.


He then joined the faculty of the Lahey Clinic’s Department of Urology as director of Kidney Transplantation. He subsequently became Chair of the Institute of Urology and Chief of the division of Surgery at Lahey. He is an internationally respected urologic surgeon having authored or edited 3 textbooks of urology and a 12 volume series entitled International Perspectives in Urology.


He has written more than 50 textbook chapters and published more than 200 peer reviewed articles in the urologic and surgical literature. In addition to his surgical career Dr. Libertino was the CEO of the Lahey Clinic and its Medical Center, and still serves on their Board of Trustees. He continues to serve as a Professor of Urology at the Tufts University School of Medicine.




Bertha Madras, Ph.D. is Professor of Psychobiology in the Department of Psychiatry, Harvard Medical School, serving at Mclean Hospital. She obtained her PhD in biochemistry from McGill University and was a post-doctoral fellow at MIT.


Her 30 year career at Harvard was interrupted for nearly 3 years when she served in the White House as Deputy Director for Demand Reduction (prevention, intervention, treatment), Office of National Drug Control Policy (ONDCP), in the Executive Office of the President of the United States, a position for which she received unanimous US Senate confirmation.


Her research has focused on addiction biology and neuropsychiatric disorders (Parkinson’s disease and attention deficit hyperactivity disorder). She has published over 200 manuscripts, book chapters, commentaries and is principal editor (PE) or co-editor (CE) of recent books: “The Cell Biology of Addiction (PE)”; “The Effects of Drug Abuse on the Human Nervous System” (PE); “Imaging of the Human Brain in Health and Disease” (CE). She has 19 issued patents.


Among other activities, Dr. Madras has recently served as: advisor to the National Football League, consultant to the United States Dept. of Justice and the World Health Organization. She has delivered more than 250 presentations globally on how drugs affect the brain and developed a Boston Museum of Science, exhibit, play, and CD, “Changing your Mind: Drugs in the Brain”, the latter licensed by the Disney Corp.


Among many awards, she received a NIH-NIDA MERIT award; NIH-NIDA Public Service Award; and the American Academy of Addiction Psychiatry Founders’ Award. The Better World Report (2006) listed her brain imaging agent, altropane, as “one of 25 technology transfer innovations that changed the world”.


Michael J. Magliochetti, PhD, MBA, is an Operating Partner with Riverside Partners, LLC, a leading private equity firm focused on investing in middle market healthcare and technology companies.  Dr. Magliochetti previously served as President and CEO of OPKO Diagnostics, LLC, a point‑of‑care in-vitro diagnostic firm and wholly owned subsidiary of OPKO Health, Inc. (OPK:NYSE).  Dr. Magliochetti executed the sales transaction of Claros Diagnostics, where he was serving as CEO, to OPKO at a premium valuation.  He originally transitioned to CEO of Claros after sourcing its platform technology at Harvard, while serving as Entrepreneur-in-Residence with Oxford Bioscience Partners LP, a life science venture capital firm.  Claros was honored as one of the Top 50 Most Innovative Companies in the World for 2011 by MIT Technology Review, 2011 Technology Innovation Award Winner by the Wall Street Journal, profiled in Popular Science and INC Magazine, among others.  Dr. Magliochetti previously served as CEO of RMH., an orthopedics company, which was acquired at a premium valuation.  Previously, he was President and CEO of HemaMetrics Corporation, a dialysis blood monitoring / diagnostic technology company, subsequently acquired by Fresenius, and UroSurge Corporation, a urology products company of which a sale transaction was executed to American Medical Systems.  He has held senior positions with the medical device company Haemonetics Corporation; the polymer products company Delta Surprenant, and an assignment with the U.S. Army Research Command.  


Dr. Magliochetti currently serves on the Boards of Robert E. Wise Foundation Board at Lahey Clinic, Tegra Medical, Enovate Medical, BioAgilytix, and Bottom Line Systems.  He has served on the Healthcare Advisory Board of Riverside Partners, Advisory Board of the Pediatric New Technology Initiatives Group at Boston Children’s Hospital, The Institute for Pediatric Innovation, and on the Board of Directors of Spire.  He has also served as Adjunct Professor of Biomedical Engineering at the University of Iowa and consulted with several early-stage medical device and pharmaceutical companies.  He holds several patents, has authored numerous technical and business publications, served on many professional panels, been a guest faculty member for the Boston-Haifa Life Sciences Initiative and has lectured at universities in the U.S. and internationally on entrepreneurship and business development.  Dr. Magliochetti holds B.S. and Ph.D. degrees in Chemical Engineering from Northeastern University and the University of Massachusetts at Amherst, respectively, and a High Technology M.B.A. from Northeastern University.


William McIlhargey, MBA. As Principal for a Management Consulting Firm specializing in the buying & selling of clinically preference products, Bill assists medical device companies to position the value of their technology. The industries served by his clients include; biotech, pharma therapeutics, contract manufacturing, surgical robotics and medical devices . . . where he contributes expertise in; identifying license opportunities, building business strategy and developing US/OUS sales distribution channels. 

Prior to consulting, Bill served as an EVP with Smith & Nephew – a worldwide device manufacturer, and VP & Officer of The DePuy Group - a Johnson & Johnson Franchise, responsible for leadership of their performance contracting strategies targeting musculoskeletal and wound management sciences.    

Bill also serves on advisory boards for BU School of Public Health and Caduceus Administration, a Washington based supply chain management group. Currently serving on the Medical Development Group’s Board of Directors, Bill has served on multiple committees and co-championed multiple Forums during his 10 year affiliations with MDG.


After a European stint with the Unites States Army, Bill earned his BA from the University of Toledo, an MBA from Fisher College at Ohio State University and received advanced management training at the University of Dayton.


more News Items
There are currently no news items posted.
more MDG Calendar

Robotic Surgery: Focus on Now and the Future

MDG Boston Sponsors


 Medical Development  Group
 POB 555
 Concord, MA 01742







 About Us
 Terms of Use
 Privacy Policy








Association Management Software Powered by YourMembership  ::  Legal